Morgan Stanley
CMMB

Morgan Stanley’s Chemomab Therapeutics CMMB Stock Holding History

Morgan Stanley’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.18K Buy
4,575
+800
+21% +$1.37K ﹤0.01% 7042
2025
Q4 		$6.23K Sell
3,775
-86,290
-96% -$229K ﹤0.01% 7012
2025
Q3 		$237K Sell
90,065
-313,469
-78% -$1.16M ﹤0.01% 5824
2025
Q2 		$1.87M Buy
403,534
+374,244
+1,278% +$1.85M ﹤0.01% 4741
2025
Q1 		$128K Buy
29,290
+3,190
+12% +$22.4K ﹤0.01% 5909
2024
Q4 		$189K Sell
26,100
-74,468
-74% -$470K ﹤0.01% 5804
2024
Q3 		$632K Buy
100,568
+98,768
+5,487% +$554K ﹤0.01% 5292
2024
Q2 		$6.57K Buy
1,800
+1,101
+158% +$3.81K ﹤0.01% 6785
2024
Q1 		$2.18K Sell
699
-34,759
-98% -$89.5K ﹤0.01% 7052
2023
Q4 		$72.3K Buy
+35,458
New +$93.4K ﹤0.01% 6267
2023
Q3 		– Sell
-25
Closed -$132 – 7627
2023
Q2 		$132 Sell
25
-1,925
-99% -$12.1K ﹤0.01% 7481
2023
Q1 		$12.4K Buy
1,950
+300
+18% +$2.35K ﹤0.01% 6807
2022
Q4 		$21.1K Buy
1,650
+100
+6% +$863 ﹤0.01% 6677
2022
Q3 		$15K Buy
1,550
+151
+11% +$1.95K ﹤0.01% 6915
2022
Q2 		$21K Buy
+1,399
New +$19.5K ﹤0.01% 6952
2022
Q1 		– Sell
-2,911
Closed -$80K – 7980
2021
Q4 		$80K Buy
2,911
+2,887
+12,029% +$102K ﹤0.01% 6566
2021
Q3 		$1K Sell
24
-17
-41% -$1.03K ﹤0.01% 7760
2021
Q2 		$3K Sell
41
-43
-51% -$4.2K ﹤0.01% 7481
2021
Q1 		$10K Sell
84
-43
-34% -$8.56K ﹤0.01% 6931
2020
Q4 		$14K Buy
+127
New +$12.2K ﹤0.01% 6543
2019
Q4 		– Sell
-170
Closed -$25K – 6657
2019
Q3 		$25K Buy
+170
New +$33.1K ﹤0.01% 5942

Other funds holding CMMB

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $240M AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $147M AUM

Morgan Stanley's CMMB Position: Q1 2026 in Review

Morgan Stanley increased its Chemomab Therapeutics (CMMB) stake by 21% in Q1 2026, buying an estimated $1.37K and bringing the position to 4,575 shares worth $7.18K. The position accounts for ﹤0.01% of the portfolio, ranked #7042.

Morgan Stanley first reported a position in CMMB in Q3 2019 and has held it in 21 quarters since. The position peaked at $1.87M in Q2 2025. 15 funds tracked by Wall St. Rank hold CMMB as of Q1 2026.

  • Morgan Stanley held 4,575 shares of Chemomab Therapeutics worth $7.18K as of Q1 2026.
  • Morgan Stanley bought 800 Chemomab Therapeutics shares in Q1 2026, an estimated $1.37K.
  • Chemomab Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7042 holding.
  • Morgan Stanley first reported a position in Chemomab Therapeutics in Q3 2019 and has held it in 21 quarters since.
  • Morgan Stanley's Chemomab Therapeutics position peaked at $1.87M in Q2 2025.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.